Role of Intralipid drug in heart protection during heart bypass surgery

Pharmacological preconditioning with Intralipid in patients undergoing Off pump coronary artery bypass surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/12/016665

Enrollment

Registered

2018-12-13

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery

Interventions

Intervention1: Intralipid 20%, 2 ml/kg: Drug (Intralipid) dose- 2ml/kg Frequency- once intraoperatively before grafting starts during OPCAB Surgery Route of administration- Intravenously Total durati

Eligibility

Inclusion criteria

Inclusion criteria: patients of either sex, aged between 18 years to 70 years posted for elective OFF PUMP CORONARY ARTERY BYPASS SURGERY (OPCAB) with left ventricular ejection fraction (LVEF) > 40 %

Exclusion criteria

Exclusion criteria: Combined valve and coronary surgery, onpump CABG, redo cardiac surgery, hyperlipidaemia, significant hepatic or renal dysfunction, uncontrolled hypertension, any disorder with immunological dysfunction (eg, malignancy or positive serological test for the HIV) in the last 6 months, preoperative treatment with nicorandil (an ATP-sensitive potassium channel opener), sulfonylurea (an ATP- sensitive potassium channel blocker)

Design outcomes

Primary

Measure	Time frame
Role of Intralipid in myocardial protection during OPCAB surgery which will be assessed with Troponin T and CK-MB serum levels measured postoperativelyTimepoint: Till 72th hour postoperatively	—

Secondary

Measure	Time frame
Hemodynamic changes intraoperatively, inotropes requirement, postoperative Ejection Fraction, lipid levels, effect on Renal function tests and Liver function testsTimepoint: Till the patient is discharged	—

Countries

India

Contacts

Public ContactGegal Pruthi

Sri Jayadeva Institute of Cardiovascular Sciences and Research

docnag10@gmail.com9739864268

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026